id: NEW:randomized_clinical_trial_quality_to_NEW:stem_cell_therapy_safety_efficacy
name: Randomized Clinical Trial Quality and Regulation â†’ Stem Cell Therapy Safety
  and Efficacy
from_node:
  node_id: NEW:randomized_clinical_trial_quality
  node_name: Randomized Clinical Trial Quality and Regulation
to_node:
  node_id: NEW:stem_cell_therapy_safety_efficacy
  node_name: Stem Cell Therapy Safety and Efficacy
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Randomized clinical trials (RCTs) with proper design elements (large sample
  sizes, control groups, systematic documentation of adverse effects and failures)
  establish the gold standard for evaluating stem cell therapies'
- 'Step 2: Regulatory monitoring and oversight systems ensure that stem cell clinical
  research activities are conducted with sufficient preclinical data and follow established
  protocols'
- 'Step 3: The iterative exchange between bench research and bedside clinical application,
  facilitated by RCT frameworks, enables identification of safety signals and efficacy
  outcomes'
- 'Step 4: Government research hospitals conducting RCTs (37 studies identified) contribute
  to the evidence base that distinguishes safe and effective stem cell applications
  from those with unfavorable risk-benefit profiles'
- 'Step 5: Higher quality RCT evidence informs clinical guidelines and regulatory
  decisions, ultimately improving the safety profile and demonstrated efficacy of
  stem cell therapies reaching patients'
evidence:
  quality_rating: B
  n_studies: 61
  primary_citation: 'Chandrashekhar Chavan et al. 2024. Stem cell therapy approaches
    for non-malignant diseases & non-haematological diseases in India: A systematic
    review. The Indian journal of medical research.'
  supporting_citations: []
description: This systematic review of 61 stem cell therapy studies in India (2001-2021)
  demonstrates that maintaining gold standard quality in stem cell therapy requires
  randomized clinical trials with rigorous design elements including large sample
  sizes, control groups, and systematic documentation of failures and adverse effects.
  The study emphasizes that robust monitoring and regulation systems in stem cell
  clinical research, combined with sufficient preclinical data and iterative bench-to-bedside
  exchanges, are essential for establishing stem cell therapy safety and efficacy.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
moderators:
- name: Research institution type
  direction: strengthens
  strength: moderate
  description: Government research hospitals conducted more RCTs (37 studies) compared
    to non-government facilities, suggesting institutional capacity affects trial
    quality
- name: Stem cell source
  direction: strengthens
  strength: moderate
  description: Autologous stem cells (75%) predominated over allogenic (18.33%), with
    bone marrow-derived cells (51%) most common - standardization of cell sources
    facilitates RCT quality
- name: Preclinical data availability
  direction: strengthens
  strength: strong
  description: Sufficient preclinical data and repeated bench-to-bedside exchanges
    strengthen the translation of RCT findings to improved safety and efficacy outcomes
